中

About Us

Path：Home > About Us

Company Profile

Wuhan HealthCare Biotechnology Co., Ltd. (SRN-CN-MF-000033113) is located in Optics Valley Precision Medicine Industry Park, and was founded on February 19, 2013. As a high-tech enterprise, the company integrates R&D, production, sales and testing services, with a strategic focus on precision medical diagnostic products for major diseases such as cancer and cardiovascular-cerebrovascular diseases.

Since its establishment, the company has been committed to developing more efficient diagnostic products with strong emphasis on independent R&D. It has built multidisciplinary R&D teams covering clinical medicine, molecular biology, microfluidics, mechanical automation and other fields. The company owns more than 10 invention patents and possesses proprietary core technology for the preparation of fluorescence in situ hybridization probes with fully independent intellectual property rights, which has reached an internationally advanced level.

Based on this patented technology, the new-generation probe hybridization incubation time is only 2 hours, reducing the total detection time of fluorescence in situ hybridization from 3 days to a few hours. The products feature higher sensitivity, specificity and excellent signal-to-noise ratio.

Meanwhile, the company has established a complete domestic and international marketing system. Its products have been introduced to more than 30 countries and regions overseas, earning a good market reputation and wide customer recognition, making it a leading brand in rapid fluorescence in situ hybridization probes worldwide.

Adhering to the tenet of “Fastness, Precision, and Beyond Expectation”, the company continues to make unremitting efforts to contribute to the development of global precision medicine.

  • 500+
    Comprehensive FISH Items
  • 100+
    IVDR Certified Products

Corporate Culture

  • Mission

    Pursue Excellent Quality and Safeguard Human Health

  • Core Values

    Integrity · Dedication · Inclusiveness · Collaboration

  • Vision

    Build an Innovation Center for Biomedical Technology
    Establish a Benchmark Enterprise in the Healthcare Industry

  • Working Principles

    Pragmatic & Innovative
    Results & Process Driven
    Boost Revenue & Cut Costs
    Grasp Essence & Explore Thoroughly

With awe and respect for life

We have chosen the health industry, which means we bear the mission and responsibility to safeguard health. This urges us to redouble our efforts, achieve technological innovation on the shoulders of predecessors with modern biomedical technology, and serve customers and patients with excellent products and superior quality.

Guided by the aspiration for self‑realization and lofty ideals

We join Kanlume, undertaking the mission and responsibility of shared growth and development. We act with integrity, dedication, inclusiveness and collaboration, keep learning and working diligently, and innovate business models at the forefront of the industry. We repay our investors and society with outstanding performance and achievements.

Certification

  • 01

    ISO 13485

  • 02

    ISO 9001

History

2025
  • Fluorescent Slide Scanner Obtained Class II Medical Device Registration Certificate.
  • FISH Automated & Intelligent Systems Obtained CE-IVDR Certification.
  • Awarded the Second Prize of Hubei Provincial Science and Technology Progress Award
  • Became the Strategic Development Platform for the Pathology Business Segment of Toujing Life.
2024
  • Awarded the 6th Batch of National Specialized, Refined, Differential and Innovative "Little Giant" Enterprise by MIIT.
  • Received Optics Valley Gazelle Enterprise Honor.
  • Fully Automated Fluorescence in situ Hybridization System Obtained Class II Medical Device Registration Certificate.
2023
  • Products deployed in 700+ domestic end-users.
  • FISH product portfolio expanded to 380+ items.
  • Upcoming launch of fully automated fluorescence scanning equipment and AI interpretation software, enabling an integrated solution for rapid, automated and intelligent FISH testing.
  • Awarded "2023 Hubei Provincial Specialized, Refined, Differential and Innovative Small and Medium-sized Enterprise".
2022
  • Ranked #1 in national FISH test volume.
  • Products deployed in 600+ domestic end-users.
  • Launched Fully Automated FISH Testing Instrument KL-200.
  • Awarded "Hubei Provincial 2022-2023 Listed Reserve Seed Enterprise".
2021
  • Secured Series B+ Financing; Products deployed in 500+ domestic end-users.
  • Awarded "Top 100 Innovative Medical Devices in China & Top 20 Innovative Enterprises" at the 5th Future Medical 100 Strong List.
  • Received 2021 Optics Valley Gazelle Enterprise Honor.
2020
  • 43 FISH & PCR Products obtained CE Certification, including 2019-nCoV Nucleic Acid Detection Kit.
  • 149 FISH Products obtained Class I Filing.
  • 22 Invention Patents Granted.
2019
  • BCR/ABL, AML1/ETO obtained NMPA Class III Registration Certificates.
  • 4 PCR Products Completed Clinical Trials.
  • Multiple Products Passed National Proficiency Testing with Full Scores; 200+ FISH Products Launched, covering 100+ Grade 3 Class A Hospitals in China and 20+ European & American countries.
2018
  • HER2, ALK obtained NMPA Class III Registration Certificates.
  • 7 FISH Class I Products Filed.
  • 50+ FISH Products Launched.
  • Medical Laboratory Practice License Obtained.
2017
  • Medical Laboratory Establishment License Obtained.
  • BCR/ABL, AML1/ETO Entered Clinical Trials.
  • Technical Breakthrough in High-Throughput Solid FISH Probe Technology.
  • Series A Financing Completed
  • R&D Initiated for Fully Automated Liquid FISH Instrument.
2016
  • ALK, HER2 Registration Application Submitted.
  • Fully Automated FISH Pretreatment System Developed.
  • Shareholding Reform Completed.
  • 4 Products Obtained CE Certification.
  • 3 Invention Patents Granted.
2015
  • GMP Certification.
  • Clinical Trials of ALK & HER2.
2014
  • GMP Facility Construction.
  • Technical Breakthrough of Fast FISH.
2013
  • Company Established